Valuation: ICAD

Market Cap 106M 90.58M 84.58M 77.6M 146M 10.09B 148M 998M 391M 5.06B 396M 388M 16.74B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 76.13M 71.09M 65.22M 123M 8.48B 125M 839M 328M 4.25B 333M 326M 14.07B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.73
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap.
7/17/25 Issuer sale

Director

1,553,657 5.8540%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+70.48% 106M
+4.16%+1.75%+23.13%+15.24% 227B
+5.97%+2.77%-0.33%-15.87% 149B
+1.67%-0.88%-17.00%+39.09% 141B
+3.05%+1.15%-49.87%+3.63% 75.37B
+1.43%-0.83%+16.91%+20.50% 53.19B
-0.09%+2.33%-17.05%-12.16% 51.88B
+4.70%+4.84%+29.39%+30.32% 43.89B
+3.64%-0.07%+39.67%+54.01% 40.86B
+2.74%+3.24%+0.88%+9.16% 33.7B
Average +2.89%+1.24%+2.57%+21.44% 81.5B
Weighted average by Cap. +3.26%+1.31%+2.46%+13.71%

Financials

2023 2024
Net sales 17.32M 14.86M 13.87M 12.73M 23.93M 1.66B 24.33M 164M 64.09M 830M 65.03M 63.61M 2.74B 19.61M 16.82M 15.71M 14.41M 27.1M 1.87B 27.54M 185M 72.57M 940M 73.62M 72.02M 3.11B
Net income -4.85M -4.16M -3.88M -3.56M -6.7M -463M -6.81M -45.81M -17.94M -232M -18.2M -17.8M -768M -5.62M -4.82M -4.5M -4.13M -7.76M -537M -7.89M -53.08M -20.78M -269M -21.09M -20.63M -890M
Net Debt -21.21M -18.19M -16.99M -15.59M -29.31M -2.03B -29.79M -200M -78.49M -1.02B -79.64M -77.9M -3.36B -16.84M -14.45M -13.49M -12.38M -23.28M -1.61B -23.66M -159M -62.34M -807M -63.25M -61.87M -2.67B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock